You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Product Overview

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

Drug-disease modelling: BPH Webinar 25th September 2019

ELITE Webcast

DRUG-DISEASE MODELLING:

The impact of early vs delayed initiation of combination therapy for BPH medical management

Wednesday, 25th Sept 2019 at 12pm and 6pm

Combodart is a registered trademark of the GlaxoSmithKline group of companies